Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EVE Health Group Limited ( (AU:EVE) ) has shared an announcement.
EVE Health Group has secured an additional $400,000 from a cornerstone investor in its latest placement, lifting total funds raised to about $1.3 million at $0.02 per share with free attaching options. The strategic investor brings pharmaceutical development and commercialisation expertise, reinforcing external confidence in EVE’s reformulation strategy and its focus on large global markets estimated at more than US$30 billion.
Proceeds from the placement will be used to advance EVE’s reformulated drug candidates in sexual health and cardiovascular segments, further develop its delivery and solubilisation technologies, and support intellectual property and regulatory activities. The strengthened funding position is expected to help EVE progress licensing or supply partnerships with larger pharmaceutical companies that can provide regulatory, manufacturing and distribution capabilities.
The most recent analyst rating on (AU:EVE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
More about EVE Health Group Limited
EVE Health Group Limited is an Australian pharmaceutical company focused on reformulating established medicines using proprietary drug delivery and solubilisation technologies to improve bioavailability, onset of action and patient convenience. Its development pipeline targets large global markets, including sexual health therapies and cardiovascular treatments, by creating differentiated products as existing patents approach expiry.
Average Trading Volume: 278,476
Technical Sentiment Signal: Sell
Current Market Cap: A$5.98M
For detailed information about EVE stock, go to TipRanks’ Stock Analysis page.